EN
Home/United States/Compare/Semaglutide, tirzepatide and every other GLP‑1 medicine in the US compared
USUnited States Medicines

Semaglutide, tirzepatide and every other GLP‑1 medicine in the US compared

Every GLP‑1 medicine sold in the US side by side: the brands, how you take each one, what their main trials found, the side effects and the makers’ prices. Not a ranking.

GLP Guidebook teamPublished Oct 18, 202615 min read41 sourcesWritten from published sources
What we checked42 sources, each one opened and linked to the sentence it supportsLast checked Oct 18, 2026 · Next review due Apr 18, 2027 · How we write

Written for the United States. Other country versions are coming.

The short answer

Five GLP‑1 medicines are sold in the US: tirzepatide, semaglutide, orforglipron, dulaglutide and liraglutide, each under one or more brands. They differ in how often you take them, whether they come as a pen, vial or pill, what they’re approved for, how much weight people lost in their trials, and price. A doctor decides which, if any, fits you.

At a glance (most searched first)

Most searched first in the US (Google Trends, last 3 months to Oct 18, 2026). Not a ranking: the order says nothing about how well they work or what they cost.

MedicineBrands and approved usesMakerHow it’s takenMain-trial weight changeCommon side effectsMakers’ price a month
TirzepatideZepbound: weight (adults); moderate-to-severe sleep apnea with obesity.8 Mounjaro: type 2 diabetes (adults and children 10+); heart risk in type 2 diabetes.9Eli Lilly8Injection once a week: single-dose pen, vial or 4-dose KwikPen815.0% to 20.9% on Zepbound, by dose, against 3.1% on placebo, over 72 weeks (SURMOUNT-1)8,11Nausea (25 to 29 in 100, against 8 in 100 on placebo), diarrhea, vomiting, constipation, stomach pain, indigestion8$299 to $699 self-pay for Zepbound vials and KwikPens, by dose; Mounjaro $499; list $499 to $1,112.1628,29,33
SemaglutideWegovy injection: weight (adults and children 12+), heart risk, MASH liver disease. Wegovy pill: weight (adults), heart risk.5 Ozempic injection and pill, and Rybelsus: type 2 diabetes, plus lowering heart risk (and, for the injection, kidney risk) in diabetes. Rybelsus is being discontinued.6,7,36Novo Nordisk5Injection once a week from a pen, or a pill once a day on an empty stomach with up to 4 ounces of water, 30 minutes before food5,714.9% on Wegovy 2.4 mg, against 2.4% on placebo, over 68 weeks (STEP 1)5,10Nausea (44 in 100 on Wegovy 2.4 mg, against 16 in 100 on placebo), diarrhea, vomiting, constipation, stomach pain5$149 to $499 self-pay, by brand and dose; list $1,027.51 (Ozempic, Rybelsus) or $1,349.02 (Wegovy)26,27,32
OrforglipronFoundayo: weight (adults)4Eli Lilly4Pill once a day, with or without food47.4% to 11.1%, by dose, against 2.1% on placebo, over 72 weeks (ATTAIN-1)4,13Nausea (26 to 35 in 100, against 10 in 100 on placebo), constipation, diarrhea, vomiting, indigestion4$149 to $349 self-pay, by dose; list price $64930,31
DulaglutideTrulicity: type 2 diabetes (adults and children 10+); lowering heart risk in type 2 diabetes. Not approved for weight.1Eli Lilly1Injection once a week, from a single-use pen1A diabetes trial: 6.6 lb (3.0 kg) lost on 1.5 mg, against 3.1 lb (1.4 kg) on placebo, over 26 weeks (US label trial, added to metformin)1Nausea (21 in 100 on 1.5 mg, against 5 in 100 on placebo), diarrhea, vomiting, stomach pain, less appetite1$389 self-pay at every dose; list price $987.1929,33
LiraglutideVictoza: type 2 diabetes (adults and children 10+); heart risk.3 Saxenda: weight (adults, and children 12+ over 132 lb). Being discontinued.2,35 Generic liraglutide: copies of both.16,17Novo Nordisk (Victoza, Saxenda); Teva and Hikma (generics)16,17Injection once a day, from a pen2,37.4% on Saxenda 3 mg, against 3.0% on placebo, over 56 weeks (SCALE)2,12Nausea (39 in 100, against 14 in 100 on placebo), diarrhea, constipation, vomiting, injection-site reactions2No self-pay price published. List: Victoza $271.76 to $815.27, by dose; Saxenda $1,349.02; generic Saxenda $1,165 (news report)32,17

Not a ranking: rows are most searched first. The trials were separate, with different people and lengths, so their numbers can’t be compared directly. Weight change is the average share of body weight lost, except dulaglutide, whose label gives pounds. Prices are the makers’ regular self-pay and list prices, checked Oct 12, 2026, the same as in our cost calculator; insured people usually pay less.

Key takeaways

  • The medicine is what works in your body; the brand is the name on the box. Semaglutide is sold as Wegovy, Ozempic and Rybelsus; tirzepatide as Zepbound and Mounjaro.5,8
  • Liraglutide is taken daily; tirzepatide, semaglutide and dulaglutide weekly. The Wegovy pill and Foundayo are daily pills for weight.2,1,4,5
  • In SURMOUNT-5, a head-to-head trial, people lost 20.2% of their weight on Zepbound and 13.7% on Wegovy over 72 weeks. Other numbers come from separate trials.14
  • Stomach effects, mainly nausea, are the most common side effects of all of them.1,2,4,5,8
  • Medicare’s $50 GLP‑1 Bridge covers three brands for weight: the Zepbound KwikPen, Wegovy (shot and pill) and Foundayo.37
Before you go further
  • This page compares FDA labels and trials. It doesn’t say which medicine suits you, and we don’t rank them: a prescriber decides.
  • Prices are the makers’ published prices, never a seller’s.
  • Talk to your doctor before starting, stopping or changing any medicine. The risks are in our side effects guide.
On this page
  1. Which medicines and brands are there?
  2. Why are there so many?
  3. Why are some pills and some injections, some weekly and some daily?
  4. Why does the same medicine have two brands?
  5. How do the results compare?
  6. Which costs more, and what does coverage change?
  7. Which one? What a doctor weighs
  8. Questions people ask
  9. How we researched this
  10. Sources

Which medicines and brands are there?

Five medicines, sold under nine brand names, plus generic liraglutide. The medicine is what works in your body; the brand is the name on the box, the way acetaminophen is sold as Tylenol.

GLP‑1 is a hormone your gut releases after you eat. These medicines copy it: they slow how fast the stomach empties and reduce hunger. Tirzepatide also copies a second gut hormone, GIP.5,8

TirzepatideZepbound, MounjaroWeekly shot. Weight and sleep apnea (Zepbound); type 2 diabetes (Mounjaro)8,9
SemaglutideWegovy, Ozempic, RybelsusWeekly shot or daily pill. Weight (Wegovy); type 2 diabetes (Ozempic, Rybelsus)5,6,7
OrforglipronFoundayoDaily pill. Weight4
DulaglutideTrulicityWeekly shot. Type 2 diabetes1
LiraglutideVictoza, Saxenda, genericsDaily shot. Weight (Saxenda); type 2 diabetes (Victoza)2,3

The full family tree, with each brand’s form and approved uses, is in GLP‑1 types, brands and how they work.

Why are there so many?

Two companies, Novo Nordisk and Eli Lilly, make all the brand-name versions, and the newer medicines differ from the older ones in how often you take them, their form, or the hormones they copy.1,2,4,5,8

  • 2005The first GLP‑1 medicine, exenatide (Byetta), was approved as a twice-daily diabetes injection. It isn’t in the table above: the FDA now lists every exenatide product (Byetta, the weekly Bydureon BCise and a generic approved in November 2024) as discontinued by its maker, so none is sold in the US.25,42
  • 2010Liraglutide (Victoza): once a day, for type 2 diabetes.3 A higher dose, Saxenda, was approved for weight on December 23, 2014.21
  • 2014Dulaglutide (Trulicity): once a week, for type 2 diabetes.1
  • 2017Semaglutide (Ozempic): once a week, for type 2 diabetes.6 Rybelsus, the first GLP‑1 pill, followed on September 20, 2019,22 and Wegovy, for weight, on June 4, 2021.19
  • 2022Tirzepatide (Mounjaro): once a week, for type 2 diabetes, and it copies two gut hormones, GIP and GLP‑1.9 Zepbound, for weight, followed on November 8, 2023.20
  • 2025The Wegovy pill (semaglutide) was approved for weight on December 22, 2025.23
  • 2026Orforglipron (Foundayo): a daily pill with no food rules, approved for weight on April 1, 2026.4,24

Generics. A generic is an FDA-approved copy made by another company once patents end. Liraglutide is the only one of these medicines with US generics: a copy of Victoza since December 2024 and of Saxenda since August 2025.16,17 There is no FDA-approved generic semaglutide or tirzepatide; when their patents run out is in Is there a generic Wegovy or Zepbound? Compounded versions, mixed by pharmacies, are not generics and are not FDA-approved.18

Why are some pills and some injections, some weekly and some daily?

It comes down to how each molecule is built: how well the gut absorbs it, and how long it stays in your blood.7,4

  • Weekly or daily. A medicine’s half-life is the time for half of it to leave your blood. It is about 13 hours for liraglutide, which is injected daily.2 It is about 5 days for dulaglutide and tirzepatide and about 1 week for semaglutide, so one injection a week is enough.1,8,5
  • Semaglutide pills (Wegovy pill, Ozempic pill, Rybelsus). Semaglutide is a peptide, a small protein, and very little of a tablet reaches the blood: about 0.4% to 1% for Rybelsus. An added ingredient, SNAC, helps it get absorbed in the stomach.7 That’s why the pill is taken first thing on an empty stomach with up to 4 ounces of water, then nothing to eat or drink for at least 30 minutes.5,7
  • Foundayo (orforglipron) is a small molecule, not a peptide, that switches on the same GLP‑1 receptor.13 Food made no clinically relevant difference to how much got into the blood, so it’s taken once a day with or without food.4

The two weight pills and the Wegovy shot are compared in detail in Wegovy pill vs Foundayo vs Wegovy injection, and the Zepbound forms in Zepbound vials vs KwikPen vs pen.

Why does the same medicine have two brands?

Because each brand is approved for a different use, sometimes at different doses.5,6,8,9

  • Ozempic and Wegovy are both semaglutide. Ozempic is for type 2 diabetes, up to 2 mg a week;6 Wegovy is for weight and heart risk, usually at 2.4 mg, with a 7.2 mg Wegovy HD dose.5 See Ozempic vs Wegovy.
  • Mounjaro and Zepbound are both tirzepatide, with the same doses up to 15 mg. Mounjaro is for type 2 diabetes; Zepbound is for weight and sleep apnea.9,8 See Mounjaro vs Zepbound.
  • Victoza and Saxenda are both liraglutide: Victoza up to 1.8 mg a day for diabetes, Saxenda 3 mg a day for weight.3,2

The approved use matters for coverage: a plan may pay for a medicine for diabetes but not for weight, as explained below.

How do the results compare?

Each medicine has its own main trial, and the trials were separate, with different people, doses and lengths, so their numbers can’t be compared directly.10,11,12,13

In each trial, people were split at random into groups. One got the medicine, the other a dummy injection or dummy pill (placebo), and both got the same diet and activity advice. The gap between the groups is what the medicine added.

Average weight change in each weight medicine’s main trial
Separate placebo-controlled trials in adults without diabetes · top dose shown · not a head-to-head comparison
Most searched first in the US (Google Trends). Not a ranking.
Zepbound (tirzepatide)−20.9%
placebo−3.1%
Wegovy (semaglutide)−14.9%
placebo−2.4%
Foundayo (orforglipron)−11.1%
placebo−2.1%
Saxenda (liraglutide)−7.4%
placebo−3.0%
The trials: liraglutide (Saxenda 3 mg, SCALE, 56 weeks), orforglipron (Foundayo 17.2 mg, ATTAIN-1, 72 weeks), semaglutide (Wegovy 2.4 mg injection, STEP 1, 68 weeks), tirzepatide (Zepbound 15 mg, SURMOUNT-1, 72 weeks). Dulaglutide isn’t shown: it was tested only in people with diabetes. Numbers from each US label.2,4,5,8

For someone starting at 220 lb (100 kg), those averages are about 16 lb (7 kg) on Saxenda, 24 lb (11 kg) on Foundayo 17.2 mg, 33 lb (15 kg) on Wegovy and 46 lb (21 kg) on Zepbound 15 mg. Some people lost much more and some very little. Each trial was paid for by the medicine’s maker.10,11,12,13 The Wegovy pill gave 13.6% in its own trial (OASIS 4), against 2.4% on placebo.5,15 Every dose and side effect is in the trial results tool.

A head-to-head trial: SURMOUNT-5. It gave 751 adults with obesity, without diabetes, either Zepbound or Wegovy at the highest dose each could take. Over 72 weeks, average weight loss was 20.2% on Zepbound and 13.7% on Wegovy. Everyone knew which medicine they had, and Eli Lilly, Zepbound’s maker, paid for it.14 More in Zepbound vs Wegovy. For type 2 diabetes, Mounjaro and Ozempic were compared head to head in SURPASS-2: see Mounjaro vs Ozempic.

Side effects are similar in kind across all of them: mostly nausea, diarrhea, vomiting and constipation, worst while the dose goes up.5,8 Each label counts them in its own trials, so the rates in the table can’t be compared directly either. Serious risks are in our side effects guide.

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan to see a year at makers’ prices. No sign-up.

Open the calculator

Which costs more, and what does coverage change?

Paying cash, the makers’ monthly prices run from $149 to $699, depending on the brand and dose; what you actually pay depends on your insurance.26,28,30

The makers’ regular self-pay prices a month, most searched medicine first (Google Trends):

  • Tirzepatide: Zepbound vials and KwikPens $299 to $699, by dose; Mounjaro $499. The Zepbound single-dose pen is sold through insurance only.28,29
  • Semaglutide: Wegovy pen $349 at doses up to 2.4 mg and $399 for Wegovy HD 7.2 mg; Wegovy pill $149 to $299; Ozempic pen $349 to $499; Ozempic pill $149 to $299.26,27
  • Orforglipron: Foundayo $149 to $349, by dose.30
  • Dulaglutide: Trulicity $389 at every dose.29
  • Liraglutide: no self-pay price published. List prices are $271.76 to $815.27 for Victoza, by dose, $1,349.02 for Saxenda at 3 mg, and $1,165 for Teva’s generic Saxenda (from a news report; Teva hasn’t published it).32,17

List prices, which insured people’s costs can be based on, run from $649 (Foundayo) to $1,349.02 (Wegovy and Saxenda) a month.31,32 Novo Nordisk is cutting the list price of Wegovy, Ozempic and Rybelsus to $675 a month from January 1, 2027.34 Every brand and dose is on our GLP‑1 prices page.

What coverage changes.

  • Medicare: by law, Part D can’t cover drugs used for weight loss,38 but it can cover these medicines for other approved uses, such as diabetes, heart risk or sleep apnea.41 From July 1, 2026, to December 31, 2027, the GLP‑1 Bridge covers the Zepbound KwikPen, Wegovy (shot and pill) and Foundayo for weight at $50 a month, for people who meet its criteria.37 See the Medicare GLP‑1 Bridge explained.
  • Employer plans: in 2025, 19% of firms with 200 or more workers covered GLP‑1s mainly for weight loss.39 See prior authorization, step by step.
  • Medicaid: 13 state programs covered GLP‑1s for obesity in January 2026.40 See Medicaid by state.

All the routes are in Who pays: insurance and Medicare.

Which one? What a doctor weighs

There is no single right choice for everyone: a prescriber looks at your health, your preferences and what you can get.

  • Your health conditions. Each brand is approved for different things: type 2 diabetes, weight, heart risk, kidney risk in diabetes, sleep apnea or MASH liver disease (see the table).5,6,8
  • Daily or weekly, and needles or pills, including whether an empty-stomach morning routine works for you.5,4
  • Side effects you’ve had before, and things that rule a medicine out, such as a personal or family history of medullary thyroid cancer or MEN 2, a rare inherited condition that causes gland tumors.5,8
  • Other medicines. The labels say not to take two GLP‑1 medicines together.5,8
  • Availability and cost: what your plan covers, and the cash price at the dose you’d likely reach. Saxenda and Rybelsus are being discontinued.35,36

Our doctor questions tool builds a list to take to the appointment.

Questions people ask

What is the difference between all the GLP‑1 medicines?

They are five different medicines: tirzepatide, semaglutide, orforglipron, dulaglutide and liraglutide. They differ in how often you take them (daily or weekly), their form (pen, vial or pill), what each brand is approved for, their trial results and their price. Tirzepatide also acts on a second gut hormone, GIP.1,2,4,5,8

Which GLP‑1 medicines are pills?

Two pills are approved for weight: the Wegovy pill (semaglutide), taken on an empty stomach with up to 4 ounces of water and a 30-minute wait, and Foundayo (orforglipron), taken with or without food. The Ozempic pill and Rybelsus are semaglutide pills for type 2 diabetes.5,4,7

Are Ozempic and Wegovy the same medicine?

Yes, both are semaglutide, made by Novo Nordisk. Ozempic is approved for type 2 diabetes, up to 2 mg a week; Wegovy is approved for weight and heart risk, usually at 2.4 mg. In the same way, Mounjaro and Zepbound are both tirzepatide.6,5,9,8

Do the trials show which GLP‑1 loses more weight?

Mostly no, because each medicine was tested in a separate trial with different people and lengths. In one head-to-head trial, SURMOUNT-5, average weight loss over 72 weeks was 20.2% on Zepbound and 13.7% on Wegovy; Zepbound’s maker paid for it.14

How much do GLP‑1 medicines cost without insurance?

The makers’ self-pay prices run from $149 to $699 a month, depending on the brand and dose: for example Zepbound vials or KwikPens $299 to $699, Wegovy pens $349, Foundayo $149 to $349 and Trulicity $389. Liraglutide brands have no published self-pay price.30,29,26,28

Is there a generic GLP‑1 in the US?

Only liraglutide: a generic copy of Victoza since December 2024 and of Saxenda since August 2025. There is no FDA-approved generic semaglutide or tirzepatide, and compounded versions are not FDA-approved.16,17,18

How we researched this

We read the current US labels for every brand, downloaded on October 18, 2026, the main trial papers and the FDA and maker approval announcements. Trial numbers match our trial results tool and prices match our cost calculator (makers’ prices checked October 12, 2026).1,5,8

Pound conversions and the 220 lb examples are our arithmetic.

Before you move on

  • Note which uses your plan covers: diabetes, weight, heart or sleep apnea.
  • Ask whether a weekly shot or a daily pill suits your routine.
  • Compare cash prices at the dose you’d likely reach.
  • Plan for stomach side effects while the dose rises.
  • Never take two GLP‑1 medicines together.
Cost calculatorTrial results toolGLP‑1 types, brands and how they work

More comparisons

USUnited StatesWegovy pill vs Foundayo vs Wegovy injection: how do the GLP‑1 pills differ from the shot?USUnited StatesZepbound vs Wegovy: which loses more weight, and how do side effects, cost and coverage compare?USUnited StatesOzempic vs Wegovy: same medicine, so what is the difference in dose, weight loss, cost and coverage?
About GLP Guidebook

The twice-monthly US update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Twice a month: FDA approvals and warnings, Medicare and Medicaid changes, and makers’ price changes. How we write

Was this page easy to understand?

Sources

  1. Eli Lilly. Trulicity (dulaglutide) US prescribing information. Revised 03/2026 (sections 1, 2, 6.1 Table 1, 12.3 and 14: 26-week placebo-controlled trial added to metformin, 972 adults). Checked Oct 18, 2026. Link
  2. Novo Nordisk. Saxenda (liraglutide) US prescribing information. Revised 02/2026 (sections 1, 2, 6.1 Table 2, 12.3 and 14.1). Checked Oct 18, 2026. Link
  3. Novo Nordisk. Victoza (liraglutide) US prescribing information. Revised 10/2025. Checked Oct 18, 2026. Link
  4. Eli Lilly. Foundayo (orforglipron) tablets US prescribing information. Revised 07/2026 (sections 1, 2, 6.1 Table 1, 12.3 food effect, 14 Table 6). Checked Oct 18, 2026. Link
  5. Novo Nordisk. Wegovy (semaglutide) injection and tablets US prescribing information. Revised 06/2026 (sections 1, 2, 6.1 Table 3, 12.3, 14.2 Tables 8 and 11). Checked Oct 18, 2026. Link
  6. Novo Nordisk. Ozempic (semaglutide) injection US prescribing information. Revised 05/2026. Checked Oct 18, 2026. Link
  7. Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets US prescribing information. Revised 1/2026 (section 2; section 12.3: SNAC, absorption in the stomach, bioavailability 0.4% to 1% for Rybelsus). Checked Oct 18, 2026. Link
  8. Eli Lilly. Zepbound (tirzepatide) US prescribing information. Revised 08/2026 (sections 1, 2, 3, 6.1 Table 1, 12.3, 14.1 Table 2). Checked Oct 18, 2026. Link
  9. Eli Lilly. Mounjaro (tirzepatide) US prescribing information. Revised 08/2026 (section 1; initial US approval 2022). Checked Oct 18, 2026. Link
  10. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185. Funded by Novo Nordisk. Link
  11. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. Funded by Eli Lilly. Link
  12. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22. PMID 26132939. Funded by Novo Nordisk. Link
  13. Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. PMID 40960239. Funded by Eli Lilly. Link
  14. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. PMID 40353578. Funded by Eli Lilly. Link
  15. Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025;393:1077-1087. PMID 40934115. Funded by Novo Nordisk. Link
  16. FDA. FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes (generic liraglutide, Victoza reference). Press release, December 23, 2024. Link
  17. Fierce Pharma (news report). With Saxenda generic, Teva launches first copycat GLP-1 for obesity. August 28, 2025 (launch, and the $1,165 monthly list price at 3 mg from a Teva spokesperson). Link
  18. FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (compounded drugs are not FDA-approved). Content current as of October 1, 2026. Link
  19. FDA. FDA approves new drug treatment for chronic weight management, first since 2014 (Wegovy). Press release, June 4, 2021. Link
  20. FDA. FDA approves new medication for chronic weight management (Zepbound). Press release, November 8, 2023. Link
  21. Novo Nordisk. Novo Nordisk receives FDA approval for Saxenda for the treatment of obesity. Company announcement, December 23, 2014. Checked Oct 18, 2026. Link
  22. PharmTech (trade press). FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus, approved September 20, 2019). September 23, 2019. Checked Oct 18, 2026. Link
  23. Novo Nordisk. Wegovy pill approved in the US as first oral GLP-1 for weight management. Company announcement, December 22, 2025. Link
  24. Eli Lilly. FDA approves Lilly’s Foundayo (orforglipron). Company announcement, April 1, 2026. Link
  25. FDA. Byetta (exenatide) NDA 021773, approved April 28, 2005. Link
  26. Novo Nordisk. NovoCare: Wegovy self-pay offer and price guide (pen $349 at 0.25 to 2.4 mg, Wegovy HD 7.2 mg $399; pill $149 to $299). Checked Oct 12, 2026. Link
  27. Novo Nordisk. Ozempic pill and pen price guide, US26NC00009, May 2026 (pen $349 for 0.25 to 1 mg, $499 for 2 mg; pill $149 to $299). Checked Oct 12, 2026. Link
  28. Eli Lilly. Zepbound coverage and savings: regular self-pay prices for single-dose vials and KwikPen ($299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 to 15 mg). Checked Oct 12, 2026. Link
  29. Eli Lilly. LillyDirect pages for Zepbound (single-dose pen through insurance only), Mounjaro ($499 a month at every dose) and Trulicity ($389 a month at every dose), lilly.com/lillydirect. Checked Oct 12, 2026. Not linked because the pages sell medicine.
  30. Eli Lilly. Foundayo coverage and savings: regular self-pay prices ($149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 and 9 mg, $349 for 14.5 and 17.2 mg). Checked Oct 12, 2026. Link
  31. Lilly USA. Information for Colorado prescribers: Foundayo (orforglipron) wholesale acquisition cost $649.00 for 30 tablets at every strength. April 2026. Link
  32. Novo Nordisk Pricing. List prices (wholesale acquisition cost): Wegovy $1,349.02 (4 pens or 30 tablets); Ozempic $1,027.51 (1 pen or 30 tablets); Rybelsus $1,027.51; Saxenda $1,349.02 for 5 pens; Victoza $543.51 for 2 pens and $815.27 for 3. Checked Oct 12, 2026. A 30-day month of Victoza 0.6 mg is half a 2-pen pack ($271.76, our arithmetic).
  33. TrumpRx.gov. Original prices (wholesale acquisition cost): Mounjaro $1,112.16; Trulicity $987.19; Zepbound KwikPen $499 (2.5 to 7.5 mg) or $699 (10 to 15 mg); Zepbound vial $1,087. Checked Oct 12, 2026.
  34. Novo Nordisk. Significant reduction in US list price for Wegovy, Ozempic and Rybelsus ($675 a month, effective January 1, 2027). News release, February 24, 2026. Link
  35. Novo Nordisk. NovoCare: Saxenda discontinuation notice (last shipments to wholesalers in late January 2027). Checked Oct 12, 2026. Link
  36. Illinois Department of Healthcare and Family Services. Provider notice, May 21, 2026: Novo Nordisk will discontinue all strengths of Rybelsus tablets. Link
  37. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: information for prescribers (July 1, 2026, to December 31, 2027; $50 copay; covers Foundayo, Wegovy injection and tablets, and Zepbound KwikPen only). Product No. 12235, June 2026. Link
  38. Social Security Act §1927(d)(2)(A), applied to Part D by §1860D-2(e)(2): drugs “when used for anorexia, weight loss, or weight gain”. Link
  39. KFF. 2025 Employer Health Benefits Survey (19% of firms with 200 or more workers cover GLP-1s primarily for weight loss). Link
  40. KFF. Medicaid coverage of and spending on GLP-1s (13 state Medicaid programs covered GLP-1s for obesity in January 2026). January 16, 2026. Link
  41. KFF. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. May 11, 2026. Link
  42. FDA, Drugs@FDA, marketing status checked October 18, 2026: Byetta (NDA 021773), Bydureon BCise (NDA 209210) and generic exenatide from Amneal (ANDA 206697, approved November 19, 2024) are all listed as “Discontinued”. FDA Drug Shortages database: “Exenatide Injection. Status: Discontinuation”. Byetta · Bydureon BCise · generic exenatide · FDA discontinuation listing

Last checked Oct 18, 2026 · Next review due Apr 18, 2027 · Report an error

How this page was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your doctor, pharmacist or prescriber before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write